Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers (Tables)

v3.24.3
Revenues from Contracts and Significant Customers (Tables)
9 Months Ended
Sep. 30, 2024
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

The table below summarizes the Company’s revenue for the periods presented:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three months ended September 30, 

​

Nine Months Ended September 30, 

($ in thousands)

    

2024

    

2023

    

2024

    

2023

Qbrexza

​

$

7,583

​

$

5,865

​

$

19,435

​

$

18,038

Accutane

​

​

3,996

​

​

4,882

​

​

15,534

​

​

15,109

Amzeeq

​

​

1,542

​

​

2,336

​

​

3,503

​

​

4,904

Zilxi

​

​

558

​

​

681

​

​

1,200

​

​

1,567

Other / legacy product revenue

​

​

950

​

​

1,515

​

​

2,842

​

​

4,787

Collaboration revenue

​

​

—

​

​

182

​

​

—

​

​

546

Revenue – related party

​

 

—

​

 

31

​

 

41

​

 

97

Other revenue

​

​

—

​

​

19,260

​

​

—

​

 

19,519

Total net revenue

​

$

14,629

​

$

34,752

​

$

42,555

​

$

64,567